PLTP

Across TCGA pan-cancer cohorts, PLTP mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PLTP data layer compared with 21 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PLTP mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLTP expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where PLTP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.128	0.952	.003	54	view →
LUAD	OS	Median	III,IV	0.747	1.000	.002	40	view →
PDAC	OS	Median	II,III,IV	0.412	0.671	.015	24	view →
GBM	DFS	Quartile	All	0.236	0.452	.023	6	view →
LSCC	OS	Median	II,III,IV	0.775	1.000	.021	2	view →
HNSC	OS	Median	IV	0.924	0.734	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PLTP–CCRCC (DFS)

Open the CCRCC breakdown →